ATF5 and cystic fibrosis: In a perspective of mitochondrial quality control–based therapy, the synthetic cell-penetrating dominant negative ATF5 peptide (Cs Bio®) should be useful to dampen the persistent UPRmt activation in CF, restoring the autophagy process (Figure 2) (Sheng et al., 2011).